Notable Labs brings on 2 development executives ahead of its first blood cancer trials

Incyte’s Hiroomi Tada joined as chief medical officer, while Aquinox’s Lloyd Mackenzie will serve as chief development officer. Tada was most recently vice president of targeted therapies and translational sciences at Incyte, where he helped guide the company’s oncology portfolio. Before that, he was a medical director for clinical development in oncology at GlaxoSmithKline, and a director of clinical research at AstraZeneca.
Read more...

;